A RIP1 con­tender fails to make the cut at GSK af­ter a fast fiz­zle in pan­cre­at­ic can­cer

Well, that didn’t last long.

Just months af­ter Glax­o­SmithK­line jumped in­to a clin­i­cal pro­gram for its RIP1 ki­nase in­hibitor GSK095 for pan­cre­at­ic can­cer, the pro­gram …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER